Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 31, 2023 | clinicaltrials |
| NCT04190433 | Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT03850028 | Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients | withdrawn | N/A | 0 | University Medical Center GroningenOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | May 1, 2023 | clinicaltrials |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients(MM) | withdrawn | Phase 4 | 0 | Al-Rasheed University CollegeOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05589844 | A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | withdrawn | Phase 1 | 0 | Ayman H QasrawiOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations(SABRE) | withdrawn | Phase 2 | 0 | Imperial College Healthcare NHS TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Oncternal Therapeutics, IncINDUSTRY | 0 | Apr 21, 2023 | clinicaltrials |
| NCT04354025 | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Apr 4, 2023 | clinicaltrials |
| NCT05038384 | Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT04311866 | Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants | withdrawn | N/A | 0 | Universidad Autonoma de Nuevo LeonOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05365100 | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL | withdrawn | Phase 1 / Phase 2 | 0 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05209308 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL(CORAL) | withdrawn | Phase 2 | 0 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02863458 | DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US | withdrawn | — | 0 | The Cleveland ClinicOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 9, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma(BRIO) | withdrawn | Phase 2 | 0 | SecuraBioINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04530695 | Diagnosis and Treatment of Periodontal Disease in Patients With AML | withdrawn | N/A | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | withdrawn | Phase 1 | 0 | HutchmedINDUSTRY | 7 | Feb 21, 2023 | clinicaltrials |
| NCT04877080 | CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL | withdrawn | Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 0 | Feb 10, 2023 | clinicaltrials |
| NCT05362331 | Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | Feb 9, 2023 | clinicaltrials |
| NCT03359733 | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03772288 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT04334174 | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas(BRENTICON-T) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT00003407 | Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | withdrawn | Phase 2 | 0 | Rush University Medical CenterOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | withdrawn | Phase 1 / Phase 2 | 0 | Alliance Foundation Trials, LLC.OTHER | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | withdrawn | Phase 1 / Phase 2 | 0 | Hackensack Meridian HealthOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients(SLAM) | withdrawn | Phase 1 / Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma(SCORE) | withdrawn | Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 21, 2022 | clinicaltrials |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | withdrawn | Phase 2 | 0 | Attaya SuvannasankhaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT01138579 | Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation(STP-LYM-01) | withdrawn | Phase 1 / Phase 2 | 0 | Technical University of MunichOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04343027 | Patient Satisfaction in the Orthopedic Surgery Clinic | withdrawn | N/A | 0 | NYU Langone HealthOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kunming Hope of Health HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | withdrawn | Phase 1 / Phase 2 | 0 | Kunming Hope of Health HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05015972 | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | withdrawn | Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | withdrawn | Phase 1 | 0 | Yazeed SawalhaOTHER | 0 | Sep 30, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2023source: clinicaltrials